+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Circuit Survival during Continuous Venovenous Hemodialysis versus Continuous Venovenous Hemofiltration

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Continuous renal replacement therapy (CRRT) technique may affect circuit lifespan. A shorter circuit life may reduce CRRT efficacy and increase costs. Methods: In a before-and-after study, we compared circuit median survival time during continuous venovenous hemofiltration (CVVH) versus continuous venovenous hemodialysis (­CVVHD). We performed log-rank mixed effects univariate analysis and Cox mixed effect regression modeling to define predictors of circuit lifespan. Results: We compared 197 ­CVVHD and 97 CVVH circuits in 39 patients. There was no overall difference in circuit lifespan. When no anticoagulation was used, median circuit survival time was shorter for CVVH circuits (5 h, 95% CI 3–7 vs. 10 h, 95% CI 8–13, p < 0.01). Moreover, CVVHD, lower platelets levels, and longer activated partial thromboplastin time independently predicted longer circuit median survival time. Conclusions: CVVHD is associated with longer circuit median survival time than CVVH when no anticoagulation is used and is an independent predictor of circuit survival.

          Related collections

          Author and article information

          Blood Purif
          Blood Purification
          S. Karger AG
          May 2020
          21 February 2020
          : 49
          : 3
          : 281-288
          aDepartment of Nephrology, Hospital del Mar, Barcelona, Spain
          bDepartment of Intensive Care, Austin Hospital, Melbourne, Victoria, Australia
          cService de Médecine Intensive et Réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
          dCentre for Integrated Critical Care, The University of Melbourne, Melbourne, Victoria, Australia
          Author notes
          *Rinaldo Bellomo, Department of Intensive Care, Austin Hospital, 145 Studley Road, Melbourne VIC 3084 (Australia), E-Mail
          504037 Blood Purif 2020;49:281–288
          © 2020 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 2, Tables: 2, Pages: 8
          Research Article


          Comment on this article